N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review
The incidence rate of prostate cancer (PCa) has risen by 3% per year from 2014 through 2019 in the United States. An estimated 34,700 people will die from PCa in 2023, corresponding to 95 deaths per day. Castration resistant prostate cancer (CRPC) is the leading cause of deaths among men with PCa. A...
Saved in:
Main Authors: | Ye Chen (Author), Tian Lan (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7
by: Balaji Chandrasekaran, et al.
Published: (2023) -
PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer
by: Yulu Zhang, et al.
Published: (2024) -
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012) -
Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment
by: Yingying Zhang, et al.
Published: (2022) -
Splice variants of androgen receptor and prostate cancer
by: Orazio Caffo, et al.
Published: (2016)